,
, Naval Medical Research
, ANRS
,
, Robert Debré Hospital
,
,
,
,
,
Britta Liedigk 15,30 , Didier Ngabo 15,29 , Martin Rudolf 15,30 , Ruth Thom 15,29 , Romy Kerber 15,30 , Martin Gabriel 15,30 , Antonino Di Caro 15,31 , Roman Wölfel 15, Takashi Kuroda) We thank Pr Dominique Lombardo, head of unit INSERM UMR_S 911, and Joseph Ciccolini (same unit, PK platform) for facilitating the implementation of favipiravir HPLC PK dosage. We also gratefully acknowledge the valuable contributions of the following persons, vol.10 ,
, Hôpital Bicêtre, vol.5
Centre International de Recherche en Infectiologie, Lyon, References 1. World Health Organization. WHO | Ebola situation reports ,
, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola, Ebola treatments and interventions, 2015.
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, pp.153-155, 2014. ,
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, pp.17-21, 2014. ,
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials, Clin Pharmacokinet, vol.55, pp.907-923, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01344917
, Report on the Deliberation Results (English version, Japanese Pharmaceuticals and Medical Devices Agency (PMDA), p.31, 2014.
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med, vol.13, p.1001967, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01327168
Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, pp.150-151, 2015. ,
Favipiravir for children with Ebola, Lancet, vol.385, pp.603-604, 2015. ,
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action, Clin Pharmacokinet, vol.49, pp.17-45, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00461125
Ebola virus dynamics in mice treated with favipiravir, Antiviral Res, vol.123, pp.70-77, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01196078
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, pp.132-137, 2015. ,
Liver aldehyde oxidase, Biochem J, vol.34, pp.764-774, 1940. ,
Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study, Clin Sci Lond Engl, vol.101, pp.173-179, 1979. ,
Viral hemorrhagic fevers, Clin Lab Med, vol.26, pp.345-386, 2006. ,
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults, Expert Opin Drug Metab Toxicol, vol.9, pp.1067-1084, 2013. ,
Pharmacokinetic changes in critical illness, Crit Care Clin, vol.22, pp.255-271, 2006. ,
The Impact of Single Nucleotide Polymorphisms on Human Aldehyde Oxidase, Drug Metab Dispos, vol.40, pp.856-864, 2012. ,
Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrob Agents Chemother, p.61, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01524308